RT Journal Article
SR Electronic
T1 EPV222/#603 Radiological response to neoadjuvant chemotherapy as indicator of optimal cytoreduction in advanced ovarian cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A117
OP A117
DO 10.1136/ijgc-2021-IGCS.293
VO 31
IS Suppl 4
A1 S Maricic
A1 A Mandic
A1 N Prvulovic Bunovic
A1 S Stojanovic
A1 I Stojic
A1 N Stanulovic
YR 2021
UL http://ijgc.bmj.com/content/31/Suppl_4/A117.2.abstract
AB Objectives The extent of tumor cytoreduction (residual tumor volume) is the most important prognostic factor in advanced ovarian cancer (AOC). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is an option in cases where optimal cytoreduction is not possible in upfront surgery. Despite that NACT did not raise the survival rate, it still showed increased cytoreduction rate, decreased surgical morbidity and good progression-free interval. The purpose of this study is to determine the role of imaging in the prediction of the extent of cytoreduction after NACT.Methods The 37 patients with AOC were included in the study. They were operated in our center after the administration of NACT. Evaluation of the response to NACT was done with CT/MRI after 3–4 cycles of NACT.Results NACT was administered in 3 or 4 cycles of Paclitaxel/Carboplatin protocol. Patients were diagnosed in FIGO stage III (29; 78,4%) or IV (8; 21,6%). Cytological (26; 70,3%) or histopathological (9; 29,7%) confirmation of malignancy was done prior chemotherapy. According to imaging, 32 subjects (86,5%) achieved a partial response (PR) to chemotherapy, 4 of them (11,8%) obtained complete response (CR) and one retained stable disease (2,7%). Out of those subjects with PR, 19 (59,4%) had optimal debulking, while 13 (40,6%) had a suboptimal debulking procedure. All 4 of the patients with CR had complete debulking, while one with SD had suboptimal debulking.Conclusions Imaging evaluation of response to NACT is a valid method to assess surgical resectability and select patients appropriate for complete cytoreduction.